ampreloxetine

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Symptomatic Neurogenic Orthostatic Hypotension

Drug Information

Target Indication

Symptomatic Neurogenic Orthostatic Hypotension

Clinical Trial

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

TBPH

Theravance Biopharma, Inc.

Related Pipeline

Neurogenic Orthostatic Hypotension

Staphylococcal Skin Infection

Gastroparesis

Acute Lung Injury (ALI) Associated With COVID-19

Healthy